This document addresses the susceptibility testing of Mycobacterium tuberculosis complex
(MTBC), clinically significant slowly and rapidly growing mycobacterial species, Nocardia …

The rifamycin antibacterials, rifampicin (rifampin), rifabutin and rifapentine, are uniquely
potent in the treatment of patients with tuberculosis and chronic staphylococcal infections …

Limited information exists on the pharmacokinetic (PK)-pharmacodynamic (PD)
relationships of drugs against Mycobacterium tuberculosis. Our aim was to identify the PK …

Screening for new antimicrobial agents is routinely conducted only against actively
replicating bacteria. However, it is now widely accepted that a physiological state of …

Treatment of intracellular bacterial infection remains both a medical and economic
challenge. Pathogens thriving or maintaining themselves in cells, or simply taking transient …

Objectives Treatment outcome of MDR-TB is critically dependent on the proper use of
second-line drugs as per the result of in vitro drug susceptibility testing (DST). We aimed to …

We compared the efficacies of 17 agents against rapidly growing and starved
Mycobacterium tuberculosis H37Rv. Few compounds have significant activity at attainable …

The therapy of mycobacterial infections is challenging for a number of reasons. Because
mycobacteria are not susceptible to many classes of antibacterial agents, treatment typically …

Background The lack of prospective, randomized, controlled trial data to guide optimal
antibiotic use in bacteraemic critically ill patients has led to a wide variety of strategies and …

The HIV-tuberculosis co-infection has caused an impact on tuberculosis epidemiology all
over the world and the efficacies of the therapeutic schemes traditionally prescribed in the …